We are live on ! Find out more
AVLSA

Atlas Venture Life Science Advisors Portfolio holdings

AUM $881M
1-Year Est. Return 160.77%
This Fund
S&P 500
This Quarter Est. Return
+23.21%
1 Year Est. Return
+160.77%
3 Year Est. Return
+483.58%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$881M
AUM Growth
+$91.3M
Cap. Flow
-$75.3M
Cap. Flow %
-8.54%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
1
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
KLRA
Kailera Therapeutics
KLRA
+$114M
2
QTTB icon
Q32 Bio
QTTB
+$5.22M

Top Sells

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$149M
2
DYN icon
Dyne Therapeutics
DYN
+$43.3M
3
KRRO icon
Korro Bio
KRRO
+$2.17M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYMR icon
1
Kymera Therapeutics
KYMR
$9.82B
$327M 37.05%
2,847,541
-1,730,467
-38% -$149M
DYN icon
2
Dyne Therapeutics
DYN
$4.68B
$151M 17.14%
6,800,099
-2,330,366
-26% -$43.3M
SION
3
Sionna Therapeutics
SION
$265M
$132M 14.95%
2,995,602
– –
KLRA
4
Kailera Therapeutics
KLRA
$2.1B
$114M 12.93%
+5,171,282
New +$114M
IRON icon
5
Disc Medicine
IRON
$3.07B
$111M 12.56%
1,513,875
– –
QTTB icon
6
Q32 Bio
QTTB
$447M
$34.6M 3.93%
2,717,106
+625,000
+30% +$5.22M
KRRO icon
7
Korro Bio
KRRO
$190M
$12.7M 1.44%
962,884
-174,265
-15% -$2.17M

Similar funds

AAA
Adams Asset Advisors Dallas, Texas $882M AUM 42% 1-Year Est. Return
FSCM
Front Street Capital Management Missoula, Montana $881M AUM 86.5% 1-Year Est. Return
CCA
Canyon Capital Advisors Dallas, Texas $882M AUM 62.77% 1-Year Est. Return
TAM
TCP Asset Management Columbus, Ohio $882M AUM 21.79% 1-Year Est. Return
FFG
Fiduciary Financial Group San Rafael, California $882M AUM 23.98% 1-Year Est. Return
MWA
Meridian Wealth Advisors Austin, Texas $880M AUM 30.15% 1-Year Est. Return
1IA
1834 Investment Advisors Milwaukee, Wisconsin $883M AUM 23.82% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $880M AUM 44.18% 1-Year Est. Return

Atlas Venture Life Science Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Atlas Venture Life Science Advisors held 7 positions worth $881M, up 12% from $790M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Atlas Venture Life Science Advisors withdrew a net $75.3M in Q2 2026, reducing 3 holdings. Its largest reduction was Kymera Therapeutics, cutting an estimated $149M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Atlas Venture Life Science Advisors opened a new position in Kailera Therapeutics worth $114M.

  • Atlas Venture Life Science Advisors's largest Q2 2026 buy was Kailera Therapeutics: 5,171,282 shares worth $114M.
  • Atlas Venture Life Science Advisors added most to Q32 Bio in Q2 2026, an estimated $5.22M increase.
  • Atlas Venture Life Science Advisors's biggest Q2 2026 reduction was Kymera Therapeutics, cutting an estimated $149M.
  • Atlas Venture Life Science Advisors's ten largest holdings make up 100% of its $881M portfolio in Q2 2026.
  • Atlas Venture Life Science Advisors opened 1 new position and closed 0 in Q2 2026.
  • Atlas Venture Life Science Advisors's portfolio value rose 12% quarter-over-quarter to $881M.

Based on Atlas Venture Life Science Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.